血清CDH13甲基化对非肌层浸润性膀胱癌行TURBT治疗后进展的预测作用

发布时间：2018-04-24 21:41

本文选题：膀胱肿瘤 + 进展　；参考：《重庆医学》2017年35期

【摘要】：目的探索血清钙黏蛋白13(CDH13)甲基化对非肌层浸润性膀胱癌行经尿道膀胱肿瘤切除术(TURBT)治疗后进展的预测作用。方法选取2010年1月至2012年1月在该院行TURBT治疗的非肌层浸润性膀胱癌患者98例,应用甲基化特异性PCR检测患者血清CDH13甲基化状态,并分析其与患者临床病理资料及术后进展情况的相关性。结果 52例(53.1%)患者血清中检测到CDH13甲基化,并且血清CDH13甲基化与肿瘤大小、分级及数目密切相关(P0.05)。在随访过程中有20例(20.4%)患者出现肿瘤进展,Kaplan-Meier分析和log-rank检验发现存在血清CDH13甲基化的患者无进展生存率低于血清CDH13未甲基化的患者,差异有统计学意义(P=0.007)。Cox回归分析显示,血清CDH13甲基化是非肌层浸润性膀胱癌行TURBT治疗后进展的独立危险因素。结论血清CDH13甲基化可作为非肌层浸润性膀胱癌行TURBT治疗后进展的预测指标。
[Abstract]:Objective to investigate the predictive effect of serum cadherin 13 CDH13 methylation on the progression of non-myometrial invasive bladder cancer treated by transurethral resection of bladder tumor (TURBT). Methods 98 patients with non-myometrial invasive bladder cancer treated with TURBT from January 2010 to January 2012 were selected and their serum CDH13 methylation status was detected by methylation-specific PCR. The correlation between clinical and pathological data and postoperative progress was analyzed. Results Serum CDH13 methylation was detected in 52 patients (53.1%), and serum CDH13 methylation was closely related to tumor size, grade and number of tumors (P 0.05). Kaplan-Meier analysis and log-rank test showed that the progressive survival rate of patients with serum CDH13 methylation was lower than that of patients with serum CDH13 unmethylation. Serum CDH13 methylation is an independent risk factor for progression of non-myometrial bladder cancer after TURBT therapy. Conclusion Serum CDH13 methylation can be used as a predictor of the progression of non-myometrial bladder cancer after TURBT therapy.
【作者单位】：徐州市肿瘤医院泌尿外科;徐州市肿瘤医院科教科;
【基金】：江苏省徐州市医学青年后备人才项目(2014007) 江苏大学临床科技发展基金项目(JLY20160064) 江苏省“六大人才高峰”资助项目(2014-WSW-066) 江苏省卫生和计划生育委员会青年科研课题项目(Q201514) 江苏省青年医学人才项目(QNRC2016395)
【分类号】：R737.14

【相似文献】